Global Oncology Biosimilars Market Research Report 2020

Publisher Name :
Date: 23-Mar-2020
No. of pages: 95
Inquire Before Buying

The global Oncology Biosimilars market is valued at US$ 474.2 million in 2020 is expected to reach US$ 2965 million by the end of 2026, growing at a CAGR of 29.6% during 2021-2026.

This report focuses on Oncology Biosimilars volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Oncology Biosimilars market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan etc.

Market Segment Analysis

The research report includes specific segments by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2015 to 2026. Understanding the segments helps in identifying the importance of different factors that aid the market growth.

Segment by Type, the Oncology Biosimilars market is segmented into

- mAb

- Immunomodulators

- Hematopoietic Agents

- G-CSF

- Others

Segment by Application

- Retail Pharmacies

- Hospital Pharmacy

- Online Pharmacy

Global Oncology Biosimilars Market: Regional Analysis

The Oncology Biosimilars market is analysed and market size information is provided by regions (countries). The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type and by Application segment in terms of sales and revenue for the period 2015-2026.

The key regions covered in the Oncology Biosimilars market report are:

North America

- U.S.

- Canada

Europe

- Germany

- France

- U.K.

- Italy

- Russia

Asia-Pacific

- China

- Japan

- South Korea

- India

- Australia

- Taiwan

- Indonesia

- Thailand

- Malaysia

- Philippines

- Vietnam

Latin America

- Mexico

- Brazil

- Argentina

Middle East & Africa

- Turkey

- Saudi Arabia

- U.A.E

Global Oncology Biosimilars Market: Competitive Analysis

This section of the report identifies various key manufacturers of the market. It helps the reader understand the strategies and collaborations that players are focusing on combat competition in the market. The comprehensive report provides a significant microscopic look at the market. The reader can identify the footprints of the manufacturers by knowing about the global revenue of manufacturers, the global price of manufacturers, and sales by manufacturers during the forecast period of 2015 to 2019.

The major players in global Oncology Biosimilars market include:

- Celltrion

- Biocon

- Dr. Reddy's Laboratories

- STADA Arzneimittel AG

- Intas Pharmaceuticals

- Pfizer

- Sandoz International

- Teva Pharmaceutical Industries Ltd

- Apotex

- BIOCAD

Global Oncology Biosimilars Market Research Report 2020

Table of Contents
1 Oncology Biosimilars Market Overview
1.1 Product Overview and Scope of Oncology Biosimilars
1.2 Oncology Biosimilars Segment by Type
1.2.1 Global Oncology Biosimilars Sales Growth Rate Comparison by Type (2021-2026)
1.2.2 mAb
1.2.3 Immunomodulators
1.2.4 Hematopoietic Agents
1.2.5 G-CSF
1.2.6 Others
1.3 Oncology Biosimilars Segment by Application
1.3.1 Oncology Biosimilars Sales Comparison by Application: 2020 VS 2026
1.3.2 Retail Pharmacies
1.3.3 Hospital Pharmacy
1.3.4 Online Pharmacy
1.4 Global Oncology Biosimilars Market Size Estimates and Forecasts
1.4.1 Global Oncology Biosimilars Revenue 2015-2026
1.4.2 Global Oncology Biosimilars Sales 2015-2026
1.4.3 Oncology Biosimilars Market Size by Region: 2020 Versus 2026
2 Global Oncology Biosimilars Market Competition by Manufacturers
2.1 Global Oncology Biosimilars Sales Market Share by Manufacturers (2015-2020)
2.2 Global Oncology Biosimilars Revenue Share by Manufacturers (2015-2020)
2.3 Global Oncology Biosimilars Average Price by Manufacturers (2015-2020)
2.4 Manufacturers Oncology Biosimilars Manufacturing Sites, Area Served, Product Type
2.5 Oncology Biosimilars Market Competitive Situation and Trends
2.5.1 Oncology Biosimilars Market Concentration Rate
2.5.2 Global Top 5 and Top 10 Players Market Share by Revenue
2.5.3 Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.6 Manufacturers Mergers & Acquisitions, Expansion Plans
2.7 Primary Interviews with Key Oncology Biosimilars Players (Opinion Leaders)
3 Oncology Biosimilars Retrospective Market Scenario by Region
3.1 Global Oncology Biosimilars Retrospective Market Scenario in Sales by Region: 2015-2020
3.2 Global Oncology Biosimilars Retrospective Market Scenario in Revenue by Region: 2015-2020
3.3 North America Oncology Biosimilars Market Facts & Figures by Country
3.3.1 North America Oncology Biosimilars Sales by Country
3.3.2 North America Oncology Biosimilars Sales by Country
3.3.3 U.S.
3.3.4 Canada
3.4 Europe Oncology Biosimilars Market Facts & Figures by Country
3.4.1 Europe Oncology Biosimilars Sales by Country
3.4.2 Europe Oncology Biosimilars Sales by Country
3.4.3 Germany
3.4.4 France
3.4.5 U.K.
3.4.6 Italy
3.4.7 Russia
3.5 Asia Pacific Oncology Biosimilars Market Facts & Figures by Region
3.5.1 Asia Pacific Oncology Biosimilars Sales by Region
3.5.2 Asia Pacific Oncology Biosimilars Sales by Region
3.5.3 China
3.5.4 Japan
3.5.5 South Korea
3.5.6 India
3.5.7 Australia
3.5.8 Taiwan
3.5.9 Indonesia
3.5.10 Thailand
3.5.11 Malaysia
3.5.12 Philippines
3.5.13 Vietnam
3.6 Latin America Oncology Biosimilars Market Facts & Figures by Country
3.6.1 Latin America Oncology Biosimilars Sales by Country
3.6.2 Latin America Oncology Biosimilars Sales by Country
3.6.3 Mexico
3.6.3 Brazil
3.6.3 Argentina
3.7 Middle East and Africa Oncology Biosimilars Market Facts & Figures by Country
3.7.1 Middle East and Africa Oncology Biosimilars Sales by Country
3.7.2 Middle East and Africa Oncology Biosimilars Sales by Country
3.7.3 Turkey
3.7.4 Saudi Arabia
3.7.5 U.A.E
4 Global Oncology Biosimilars Historic Market Analysis by Type
4.1 Global Oncology Biosimilars Sales Market Share by Type (2015-2020)
4.2 Global Oncology Biosimilars Revenue Market Share by Type (2015-2020)
4.3 Global Oncology Biosimilars Price Market Share by Type (2015-2020)
4.4 Global Oncology Biosimilars Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End
5 Global Oncology Biosimilars Historic Market Analysis by Application
5.1 Global Oncology Biosimilars Sales Market Share by Application (2015-2020)
5.2 Global Oncology Biosimilars Revenue Market Share by Application (2015-2020)
5.3 Global Oncology Biosimilars Price by Application (2015-2020)
6 Company Profiles and Key Figures in Oncology Biosimilars Business
6.1 Celltrion
6.1.1 Corporation Information
6.1.2 Celltrion Description, Business Overview and Total Revenue
6.1.3 Celltrion Oncology Biosimilars Sales, Revenue and Gross Margin (2015-2020)
6.1.4 Celltrion Products Offered
6.1.5 Celltrion Recent Development
6.2 Biocon
6.2.1 Biocon Oncology Biosimilars Production Sites and Area Served
6.2.2 Biocon Description, Business Overview and Total Revenue
6.2.3 Biocon Oncology Biosimilars Sales, Revenue and Gross Margin (2015-2020)
6.2.4 Biocon Products Offered
6.2.5 Biocon Recent Development
6.3 Dr. Reddy's Laboratories
6.3.1 Dr. Reddy's Laboratories Oncology Biosimilars Production Sites and Area Served
6.3.2 Dr. Reddy's Laboratories Description, Business Overview and Total Revenue
6.3.3 Dr. Reddy's Laboratories Oncology Biosimilars Sales, Revenue and Gross Margin (2015-2020)
6.3.4 Dr. Reddy's Laboratories Products Offered
6.3.5 Dr. Reddy's Laboratories Recent Development
6.4 STADA Arzneimittel AG
6.4.1 STADA Arzneimittel AG Oncology Biosimilars Production Sites and Area Served
6.4.2 STADA Arzneimittel AG Description, Business Overview and Total Revenue
6.4.3 STADA Arzneimittel AG Oncology Biosimilars Sales, Revenue and Gross Margin (2015-2020)
6.4.4 STADA Arzneimittel AG Products Offered
6.4.5 STADA Arzneimittel AG Recent Development
6.5 Intas Pharmaceuticals
6.5.1 Intas Pharmaceuticals Oncology Biosimilars Production Sites and Area Served
6.5.2 Intas Pharmaceuticals Description, Business Overview and Total Revenue
6.5.3 Intas Pharmaceuticals Oncology Biosimilars Sales, Revenue and Gross Margin (2015-2020)
6.5.4 Intas Pharmaceuticals Products Offered
6.5.5 Intas Pharmaceuticals Recent Development
6.6 Pfizer
6.6.1 Pfizer Oncology Biosimilars Production Sites and Area Served
6.6.2 Pfizer Description, Business Overview and Total Revenue
6.6.3 Pfizer Oncology Biosimilars Sales, Revenue and Gross Margin (2015-2020)
6.6.4 Pfizer Products Offered
6.6.5 Pfizer Recent Development
6.7 Sandoz International
6.6.1 Sandoz International Oncology Biosimilars Production Sites and Area Served
6.6.2 Sandoz International Description, Business Overview and Total Revenue
6.6.3 Sandoz International Oncology Biosimilars Sales, Revenue and Gross Margin (2015-2020)
6.4.4 Sandoz International Products Offered
6.7.5 Sandoz International Recent Development
6.8 Teva Pharmaceutical Industries Ltd
6.8.1 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Production Sites and Area Served
6.8.2 Teva Pharmaceutical Industries Ltd Description, Business Overview and Total Revenue
6.8.3 Teva Pharmaceutical Industries Ltd Oncology Biosimilars Sales, Revenue and Gross Margin (2015-2020)
6.8.4 Teva Pharmaceutical Industries Ltd Products Offered
6.8.5 Teva Pharmaceutical Industries Ltd Recent Development
6.9 Apotex
6.9.1 Apotex Oncology Biosimilars Production Sites and Area Served
6.9.2 Apotex Description, Business Overview and Total Revenue
6.9.3 Apotex Oncology Biosimilars Sales, Revenue and Gross Margin (2015-2020)
6.9.4 Apotex Products Offered
6.9.5 Apotex Recent Development
6.10 BIOCAD
6.10.1 BIOCAD Oncology Biosimilars Production Sites and Area Served
6.10.2 BIOCAD Description, Business Overview and Total Revenue
6.10.3 BIOCAD Oncology Biosimilars Sales, Revenue and Gross Margin (2015-2020)
6.10.4 BIOCAD Products Offered
6.10.5 BIOCAD Recent Development
7 Oncology Biosimilars Manufacturing Cost Analysis
7.1 Oncology Biosimilars Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Key Raw Materials Price Trend
7.1.3 Key Suppliers of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.3 Manufacturing Process Analysis of Oncology Biosimilars
7.4 Oncology Biosimilars Industrial Chain Analysis
8 Marketing Channel, Distributors and Customers
8.1 Marketing Channel
8.2 Oncology Biosimilars Distributors List
8.3 Oncology Biosimilars Customers
9 Market Dynamics
9.1 Market Trends
9.2 Opportunities and Drivers
9.3 Challenges
9.4 Porter's Five Forces Analysis
10 Global Market Forecast
10.1 Global Oncology Biosimilars Market Estimates and Projections by Type
10.1.1 Global Forecasted Sales of Oncology Biosimilars by Type (2021-2026)
10.1.2 Global Forecasted Revenue of Oncology Biosimilars by Type (2021-2026)
10.2 Oncology Biosimilars Market Estimates and Projections by Application
10.2.1 Global Forecasted Sales of Oncology Biosimilars by Application (2021-2026)
10.2.2 Global Forecasted Revenue of Oncology Biosimilars by Application (2021-2026)
10.3 Oncology Biosimilars Market Estimates and Projections by Region
10.3.1 Global Forecasted Sales of Oncology Biosimilars by Region (2021-2026)
10.3.2 Global Forecasted Revenue of Oncology Biosimilars by Region (2021-2026)
10.4 North America Oncology Biosimilars Estimates and Projections (2021-2026)
10.5 Europe Oncology Biosimilars Estimates and Projections (2021-2026)
10.6 Asia Pacific Oncology Biosimilars Estimates and Projections (2021-2026)
10.7 Latin America Oncology Biosimilars Estimates and Projections (2021-2026)
10.8 Middle East and Africa Oncology Biosimilars Estimates and Projections (2021-2026)
11 Research Finding and Conclusion
12 Methodology and Data Source
12.1 Methodology/Research Approach
12.1.1 Research Programs/Design
12.1.2 Market Size Estimation
12.1.3 Market Breakdown and Data Triangulation
12.2 Data Source
12.2.1 Secondary Sources
12.2.2 Primary Sources
12.3 Author List
12.4 Disclaimer
List of Tables
Table 1. Global Oncology Biosimilars Sales (K g) Growth Rate Comparison by Type (2015-2026)
Table 2. Global Oncology Biosimilars Sales (K g) Comparison by Application: 2020 VS 2026
Table 3. Global Oncology Biosimilars Market Size by Type (K g) (US$ Million) (2020 VS 2026)
Table 4. Global Key Oncology Biosimilars Manufacturers Covered in This Study
Table 5. Global Oncology Biosimilars Sales (K g) by Manufacturers (2015-2020)
Table 6. Global Oncology Biosimilars Sales Share by Manufacturers (2015-2020)
Table 7. Global Oncology Biosimilars Revenue (Million USD) by Manufacturers (2015-2020)
Table 8. Global Oncology Biosimilars Revenue Share by Manufacturers (2015-2020)
Table 9. Global Market Oncology Biosimilars Average Price (USD/Unit) of Key Manufacturers (2015-2020)
Table 10. Manufacturers Oncology Biosimilars Sales Sites and Area Served
Table 11. Manufacturers Oncology Biosimilars Product Types
Table 12. Global Oncology Biosimilars Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 13. Global Oncology Biosimilars by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Oncology Biosimilars as of 2019)
Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 15. Main Points Interviewed from Key Oncology Biosimilars Players
Table 16. Global Oncology Biosimilars Sales (K g) by Region (2015-2020)
Table 17. Global Oncology Biosimilars Sales Market Share by Region (2015-2020)
Table 18. Global Oncology Biosimilars Revenue (Million US$) by Region (2015-2020)
Table 19. Global Oncology Biosimilars Revenue Market Share by Region (2015-2020)
Table 20. North America Oncology Biosimilars Sales by Country (2015-2020) (K g)
Table 21. North America Oncology Biosimilars Sales Market Share by Country (2015-2020)
Table 22. North America Oncology Biosimilars Revenue by Country (2015-2020) (US$ Million)
Table 23. North America Oncology Biosimilars Revenue Market Share by Country (2015-2020)
Table 24. Europe Oncology Biosimilars Sales by Country (2015-2020) (K g)
Table 25. Europe Oncology Biosimilars Sales Market Share by Country (2015-2020)
Table 26. Europe Oncology Biosimilars Revenue by Country (2015-2020) (US$ Million)
Table 27. Europe Oncology Biosimilars Revenue Market Share by Country (2015-2020)
Table 28. Asia Pacific Oncology Biosimilars Sales by Region (2015-2020) (K g)
Table 29. Asia Pacific Oncology Biosimilars Sales Market Share by Region (2015-2020)
Table 30. Asia Pacific Oncology Biosimilars Revenue by Region (2015-2020) (US$ Million)
Table 31. Asia Pacific Oncology Biosimilars Revenue Market Share by Region (2015-2020)
Table 32. Latin America Oncology Biosimilars Sales by Country (2015-2020) (K g)
Table 33. Latin America Oncology Biosimilars Sales Market Share by Country (2015-2020)
Table 34. Latin America Oncology Biosimilars Revenue by Country (2015-2020) (US$ Million)
Table 35. Latin America Oncology Biosimilars Revenue Market Share by Country (2015-2020)
Table 36. Middle East and Africa Oncology Biosimilars Sales by Country (2015-2020) (K g)
Table 37. Middle East and Africa Oncology Biosimilars Sales Market Share by Country (2015-2020)
Table 38. Middle East and Africa Oncology Biosimilars Revenue by Country (2015-2020) (US$ Million)
Table 39. Middle East and Africa Oncology Biosimilars Revenue Market Share by Country (2015-2020)
Table 40. Global Oncology Biosimilars Sales (K g) by Type (2015-2020)
Table 41. Global Oncology Biosimilars Sales Share by Type (2015-2020)
Table 42. Global Oncology Biosimilars Revenue (Million US$) by Type (2015-2020)
Table 43. Global Oncology Biosimilars Revenue Share by Type (2015-2020)
Table 44. Global Oncology Biosimilars Price (USD/Unit) by Type (2015-2020)
Table 45. Global Oncology Biosimilars Sales (K g) by Application (2015-2020)
Table 46. Global Oncology Biosimilars Sales Market Share by Application (2015-2020)
Table 47. Global Oncology Biosimilars Sales Growth Rate by Application (2015-2020)
Table 48. Celltrion Oncology Biosimilars Corporation Information
Table 49. Celltrion Description and Business Overview
Table 50. Celltrion Oncology Biosimilars Sales (K g), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 51. Celltrion Main Product
Table 52. Celltrion Recent Development
Table 53. Biocon Oncology Biosimilars Corporation Information
Table 54. Biocon Corporation Information
Table 55. Biocon Oncology Biosimilars Sales (K g), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 56. Biocon Main Product
Table 57. Biocon Recent Development
Table 58. Dr. Reddy's Laboratories Oncology Biosimilars Corporation Information
Table 59. Dr. Reddy's Laboratories Corporation Information
Table 60. Dr. Reddy's Laboratories Oncology Biosimilars Sales (K g), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 61. Dr. Reddy's Laboratories Main Product
Table 62. Dr. Reddy's Laboratories Recent Development
Table 63. STADA Arzneimittel AG Oncology Biosimilars Corporation Information
Table 64. STADA Arzneimittel AG Corporation Information
Table 65. STADA Arzneimittel AG Oncology Biosimilars Sales (K g), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 66. STADA Arzneimittel AG Main Product
Table 67. STADA Arzneimittel AG Recent Development
Table 68. Intas Pharmaceuticals Oncology Biosimilars Corporation Information
Table 69. Intas Pharmaceuticals Corporation Information
Table 70. Intas Pharmaceuticals Oncology Biosimilars Sales (K g), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 71. Intas Pharmaceuticals Main Product
Table 72. Intas Pharmaceuticals Recent Development
Table 73. Pfizer Oncology Biosimilars Corporation Information
Table 74. Pfizer Corporation Information
Table 75. Pfizer Oncology Biosimilars Sales (K g), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 76. Pfizer Main Product
Table 77. Pfizer Recent Development
Table 78. Sandoz International Oncology Biosimilars Corporation Information
Table 79. Sandoz International Corporation Information
Table 80. Sandoz International Oncology Biosimilars Sales (K g), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 81. Sandoz International Main Product
Table 82. Sandoz International Recent Development
Table 83. Teva Pharmaceutical Industries Ltd Oncology Biosimilars Corporation Information
Table 84. Teva Pharmaceutical Industries Ltd Corporation Information
Table 85. Teva Pharmaceutical Industries Ltd Oncology Biosimilars Sales (K g), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 86. Teva Pharmaceutical Industries Ltd Main Product
Table 87. Teva Pharmaceutical Industries Ltd Recent Development
Table 88. Apotex Oncology Biosimilars Corporation Information
Table 89. Apotex Corporation Information
Table 90. Apotex Oncology Biosimilars Sales (K g), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 91. Apotex Main Product
Table 92. Apotex Recent Development
Table 93. BIOCAD Oncology Biosimilars Corporation Information
Table 94. BIOCAD Corporation Information
Table 95. BIOCAD Oncology Biosimilars Sales (K g), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2015-2020)
Table 96. BIOCAD Main Product
Table 97. BIOCAD Recent Development
Table 98. Sales Base and Market Concentration Rate of Raw Material
Table 99. Key Suppliers of Raw Materials
Table 100. Oncology Biosimilars Distributors List
Table 101. Oncology Biosimilars Customers List
Table 102. Market Key Trends
Table 103. Key Opportunities and Drivers: Impact Analysis (2021-2026)
Table 104. Key Challenges
Table 105. Global Oncology Biosimilars Sales (K g) Forecast by Type (2021-2026)
Table 106. Global Oncology Biosimilars Sales Market Share Forecast by Type (2021-2026)
Table 107. Global Oncology Biosimilars Revenue (Million US$) Forecast by Type (2021-2026)
Table 108. Global Oncology Biosimilars Revenue (Million US$) Market Share Forecast by Type (2021-2026)
Table 109. Global Oncology Biosimilars Sales (K g) Forecast by Application (2021-2026)
Table 110. Global Oncology Biosimilars Revenue (Million US$) Forecast by Application (2021-2026)
Table 111. Global Oncology Biosimilars Sales (K g) Forecast by Region (2021-2026)
Table 112. Global Oncology Biosimilars Sales Market Share Forecast by Region (2021-2026)
Table 113. Global Oncology Biosimilars Revenue Forecast by Region (2021-2026) (US$ Million)
Table 114. Global Oncology Biosimilars Revenue Market Share Forecast by Region (2021-2026)
Table 115. Research Programs/Design for This Report
Table 116. Key Data Information from Secondary Sources
Table 117. Key Data Information from Primary Sources
List of Figures
Figure 1. Picture of Oncology Biosimilars
Figure 2. Global Oncology Biosimilars Sales Market Share by Type: 2020 VS 2026
Figure 3. mAb Product Picture
Figure 4. Immunomodulators Product Picture
Figure 5. Hematopoietic Agents Product Picture
Figure 6. G-CSF Product Picture
Figure 7. Others Product Picture
Figure 8. Global Oncology Biosimilars Consumption Market Share by Application: 2020 VS 2026
Figure 9. Retail Pharmacies
Figure 10. Hospital Pharmacy
Figure 11. Online Pharmacy
Figure 12. Global Oncology Biosimilars Market Size 2015-2026 (US$ Million)
Figure 13. Global Oncology Biosimilars Sales Capacity (K g) (2015-2026)
Figure 14. Global Oncology Biosimilars Market Size Market Share by Region: 2020 Versus 2026
Figure 15. Oncology Biosimilars Sales Share by Manufacturers in 2020
Figure 16. Global Oncology Biosimilars Revenue Share by Manufacturers in 2019
Figure 17. The Global 5 and 10 Largest Players: Market Share by Oncology Biosimilars Revenue in 2019
Figure 18. Oncology Biosimilars Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2015 VS 2019
Figure 19. Global Oncology Biosimilars Sales Market Share by Region (2015-2020)
Figure 20. Global Oncology Biosimilars Sales Market Share by Region in 2019
Figure 21. Global Oncology Biosimilars Revenue Market Share by Region (2015-2020)
Figure 22. Global Oncology Biosimilars Revenue Market Share by Region in 2019
Figure 23. North America Oncology Biosimilars Sales Market Share by Country in 2019
Figure 24. North America Oncology Biosimilars Revenue Market Share by Country in 2019
Figure 25. U.S. Oncology Biosimilars Sales Growth Rate (2015-2020) (K g)
Figure 26. U.S. Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million)
Figure 27. Canada Oncology Biosimilars Sales Growth Rate (2015-2020) (K g)
Figure 28. Canada Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million)
Figure 29. Europe Oncology Biosimilars Sales Market Share by Country in 2019
Figure 30. Europe Oncology Biosimilars Revenue Market Share by Country in 2019
Figure 31. Germany Oncology Biosimilars Sales Growth Rate (2015-2020) (K g)
Figure 32. Germany Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million)
Figure 33. France Oncology Biosimilars Sales Growth Rate (2015-2020) (K g)
Figure 34. France Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million)
Figure 35. U.K. Oncology Biosimilars Sales Growth Rate (2015-2020) (K g)
Figure 36. U.K. Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million)
Figure 37. Italy Oncology Biosimilars Sales Growth Rate (2015-2020) (K g)
Figure 38. Italy Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million)
Figure 39. Russia Oncology Biosimilars Sales Growth Rate (2015-2020) (K g)
Figure 40. Russia Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million)
Figure 41. Asia Pacific Oncology Biosimilars Sales Market Share by Region in 2019
Figure 42. Asia Pacific Oncology Biosimilars Revenue Market Share by Region in 2019
Figure 43. China Oncology Biosimilars Sales Growth Rate (2015-2020) (K g)
Figure 44. China Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million)
Figure 45. Japan Oncology Biosimilars Sales Growth Rate (2015-2020) (K g)
Figure 46. Japan Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million)
Figure 47. South Korea Oncology Biosimilars Sales Growth Rate (2015-2020) (K g)
Figure 48. South Korea Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million)
Figure 49. India Oncology Biosimilars Sales Growth Rate (2015-2020) (K g)
Figure 50. India Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million)
Figure 51. Australia Oncology Biosimilars Sales Growth Rate (2015-2020) (K g)
Figure 52. Australia Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million)
Figure 53. Taiwan Oncology Biosimilars Sales Growth Rate (2015-2020) (K g)
Figure 54. Taiwan Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million)
Figure 55. Indonesia Oncology Biosimilars Sales Growth Rate (2015-2020) (K g)
Figure 56. Indonesia Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million)
Figure 57. Thailand Oncology Biosimilars Sales Growth Rate (2015-2020) (K g)
Figure 58. Thailand Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million)
Figure 59. Malaysia Oncology Biosimilars Sales Growth Rate (2015-2020) (K g)
Figure 60. Malaysia Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million)
Figure 61. Philippines Oncology Biosimilars Sales Growth Rate (2015-2020) (K g)
Figure 62. Philippines Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million)
Figure 63. Vietnam Oncology Biosimilars Sales Growth Rate (2015-2020) (K g)
Figure 64. Vietnam Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million)
Figure 65. Latin America Oncology Biosimilars Sales Market Share by Country in 2019
Figure 66. Latin America Oncology Biosimilars Revenue Market Share by Country in 2019
Figure 67. Mexico Oncology Biosimilars Sales Growth Rate (2015-2020) (K g)
Figure 68. Mexico Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million)
Figure 69. Brazil Oncology Biosimilars Sales Growth Rate (2015-2020) (K g)
Figure 70. Brazil Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million)
Figure 71. Argentina Oncology Biosimilars Sales Growth Rate (2015-2020) (K g)
Figure 72. Argentina Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million)
Figure 73. Middle East and Africa Oncology Biosimilars Sales Market Share by Country in 2019
Figure 74. Middle East and Africa Oncology Biosimilars Revenue Market Share by Country in 2019
Figure 75. Turkey Oncology Biosimilars Sales Growth Rate (2015-2020) (K g)
Figure 76. Turkey Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million)
Figure 77. Saudi Arabia Oncology Biosimilars Sales Growth Rate (2015-2020) (K g)
Figure 78. Saudi Arabia Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million)
Figure 79. U.A.E Oncology Biosimilars Sales Growth Rate (2015-2020) (K g)
Figure 80. U.A.E Oncology Biosimilars Revenue Growth Rate (2015-2020) (US$ Million)
Figure 81. Sales Market Share of Oncology Biosimilars by Type (2015-2020)
Figure 82. Sales Market Share of Oncology Biosimilars by Type in 2019
Figure 83. Revenue Share of Oncology Biosimilars by Type (2015-2020)
Figure 84. Revenue Market Share of Oncology Biosimilars by Type in 2019
Figure 85. Global Oncology Biosimilars Sales Growth by Type (2015-2020) (K g)
Figure 86. Global Oncology Biosimilars Sales Market Share by Application (2015-2020)
Figure 87. Global Oncology Biosimilars Sales Market Share by Application in 2019
Figure 88. Global Revenue Share of Oncology Biosimilars by Application (2015-2020)
Figure 89. Global Revenue Share of Oncology Biosimilars by Application in 2020
Figure 90. Celltrion Total Revenue (US$ Million): 2019 Compared with 2018
Figure 91. Biocon Total Revenue (US$ Million): 2019 Compared with 2018
Figure 92. Dr. Reddy's Laboratories Total Revenue (US$ Million): 2019 Compared with 2018
Figure 93. STADA Arzneimittel AG Total Revenue (US$ Million): 2019 Compared with 2018
Figure 94. Intas Pharmaceuticals Total Revenue (US$ Million): 2019 Compared with 2018
Figure 95. Pfizer Total Revenue (US$ Million): 2019 Compared with 2018
Figure 96. Sandoz International Total Revenue (US$ Million): 2019 Compared with 2018
Figure 97. Teva Pharmaceutical Industries Ltd Total Revenue (US$ Million): 2019 Compared with 2018
Figure 98. Apotex Total Revenue (US$ Million): 2019 Compared with 2018
Figure 99. BIOCAD Total Revenue (US$ Million): 2019 Compared with 2018
Figure 100. Price Trend of Key Raw Materials
Figure 101. Manufacturing Cost Structure of Oncology Biosimilars
Figure 102. Manufacturing Process Analysis of Oncology Biosimilars
Figure 103. Oncology Biosimilars Industrial Chain Analysis
Figure 104. Channels of Distribution
Figure 105. Distributors Profiles
Figure 106. Porter's Five Forces Analysis
Figure 107. North America Oncology Biosimilars Sales (K g) and Growth Rate Forecast (2021-2026)
Figure 108. North America Oncology Biosimilars Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 109. Europe Oncology Biosimilars Sales (K g) and Growth Rate Forecast (2021-2026)
Figure 110. Europe Oncology Biosimilars Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 111. Latin America Oncology Biosimilars Sales (K g) and Growth Rate Forecast (2021-2026)
Figure 112. Latin America Oncology Biosimilars Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 113. Middle East and Africa Oncology Biosimilars Sales (K g) and Growth Rate Forecast (2021-2026)
Figure 114. Middle East and Africa Oncology Biosimilars Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 115. Asia Pacific Oncology Biosimilars Sales (K g) and Growth Rate Forecast (2021-2026)
Figure 116. Asia Pacific Oncology Biosimilars Revenue (Million US$) and Growth Rate Forecast (2021-2026)
Figure 117. Bottom-up and Top-down Approaches for This Report
Figure 118. Data Triangulation
Figure 119. Key Executives Interviewed
  • Global Biosimilar Drug Market Growth 2020-2025
    Published: 16-Sep-2020        Price: US 3660 Onwards        Pages: 132
    According to this study, over the next five years the Biosimilar Drug market will register a xx%% CAGR in terms of revenue, the global market size will reach $ xx million by 2025, from $ xx million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Biosimilar Drug business, shared in Chapter 3. This report presents a comprehensive overview, market shares, and growth opportunities of Biosimilar Drug market by product type, a......
  • COVID-19 World Adalimumab Biosimilar Market Research Report (by Product Type, End-User / Application and Regions / Countries)
    Published: 13-Sep-2020        Price: US 2800 Onwards        Pages: 94
    Summary This report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions. The report includes as follows: The report provides current data, historical overview and future forecast. The report includes an in-depth analysis of the Global market for Adalimumab Biosimilar , covering Global ......
  • 2020-2029 Report on Global Biosimilar Drug Market by Player, Region, Type, Application and Sales Channel
    Published: 07-Sep-2020        Price: US 2500 Onwards        Pages: 121
    The global Biosimilar Drug market was valued at $XX million in 2019, and MAResearch analysts predict the global market size will reach $XX million by the end of 2029, growing at a CAGR of XX% between 2020 and 2029. Since the COVID-19 virus outbreak in December 2019, the disease has spread to over 210 countries and territories around the world and 2 international conveyances. The global impacts of COVID-19 are already starting to be felt, and will significantly affect this industry......
  • COVID-19 World Oncology Biosimilars Market Research Report (by Product Type, End-User / Application and Regions / Countries)
    Published: 05-Sep-2020        Price: US 2800 Onwards        Pages: 98
    Summary This report includes market status and forecast of global and major regions, with introduction of vendors, regions, product types and end industries; and this report counts product types and end industries in global and major regions. The report includes as follows: The report provides current data, historical overview and future forecast. The report includes an in-depth analysis of the Global market for Oncology Biosimilars , covering Global t......
  • (COVID-19 Version) Global Biologics and Biosimilars Market Status (2015-2019) and Forecast (2020-2025) by Region, Product Type & End-Use
    Published: 04-Sep-2020        Price: US 3000 Onwards        Pages: 132
    Summary A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.A biosimilar in this report is a biologic medical product which is copy of an original product t......
  • (COVID-19 Version) Global Biosimilars Market Status (2015-2019) and Forecast (2020-2025) by Region, Product Type & End-Use
    Published: 03-Sep-2020        Price: US 3000 Onwards        Pages: 98
    Summary A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product which is almost an identical copy of an original product that is manufactured by a different company. The report forecast global Biosimilars market to grow to reach xxx Million USD in 2020 with a CAGR of xx% during the period 2020-2025 due to coronavirus situation. The report offers detailed coverage of Biosimilars industry and main marke......
  • Global Biosimilar Monoclonal Antibodies Market Size, Manufacturers, Supply Chain, Sales Channel and Clients, 2020-2026
    Published: 02-Sep-2020        Price: US 5900 Onwards        Pages: 116
    Biosimilar Monoclonal Antibodies market is segmented by region, by country, company, type, application and by sales channels. Players, stakeholders, and other participants in the global Biosimilar Monoclonal Antibodies market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by region, by country, company, type, application and by sales channels for the period 2015-2026. Segment by Type,......
  • Global and China Biosimilars Market Insights, Forecast to 2026
    Published: 01-Sep-2020        Price: US 3900 Onwards        Pages: 129
    Biosimilars market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Biosimilars market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2015-2026. Segment by Type, the Biosimilars market is segmented into R......
  • 2015-2025 Global Biosimilars Market Research by Type, End-Use and Region (COVID-19 Version)
    Published: 31-Aug-2020        Price: US 2900 Onwards        Pages: 115
    Summary A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product which is almost an identical copy of an original product that is manufactured by a different company. The global Biosimilars market is expected to reach xxx Million USD by 2025, with a CAGR of xx% from 2020 to 2025. Further key aspects of the report indicate that: Chapter 1: Market Definition and Segment by Type, End-Use & Major Regions Ma......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs